CN101679397A - 具有nos抑制活性的喹诺酮、四氢喹啉及其相关化合物 - Google Patents

具有nos抑制活性的喹诺酮、四氢喹啉及其相关化合物 Download PDF

Info

Publication number
CN101679397A
CN101679397A CN200880017025A CN200880017025A CN101679397A CN 101679397 A CN101679397 A CN 101679397A CN 200880017025 A CN200880017025 A CN 200880017025A CN 200880017025 A CN200880017025 A CN 200880017025A CN 101679397 A CN101679397 A CN 101679397A
Authority
CN
China
Prior art keywords
optionally substituted
mammal
compound
group
comprises administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880017025A
Other languages
English (en)
Chinese (zh)
Inventor
史恩·玛达佛
杰罗·瑞姆挪斯
苏曼·拉克希
琼安·派特曼
苏哈希·C·安呢迪
约翰·安德鲁斯
彼德·多夫
莎拉·希佛曼
保罗·瑞恩顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuraxon Inc
Original Assignee
Neuraxon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39775375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101679397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuraxon Inc filed Critical Neuraxon Inc
Publication of CN101679397A publication Critical patent/CN101679397A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200880017025A 2007-03-23 2008-03-25 具有nos抑制活性的喹诺酮、四氢喹啉及其相关化合物 Pending CN101679397A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89682907P 2007-03-23 2007-03-23
US60/896,829 2007-03-23
PCT/CA2008/000569 WO2008116308A1 (en) 2007-03-23 2008-03-25 Quinolone and tetrahydroquinoline and related compounds having nos inhibitory activity

Publications (1)

Publication Number Publication Date
CN101679397A true CN101679397A (zh) 2010-03-24

Family

ID=39775375

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880017025A Pending CN101679397A (zh) 2007-03-23 2008-03-25 具有nos抑制活性的喹诺酮、四氢喹啉及其相关化合物

Country Status (14)

Country Link
US (1) US8173813B2 (https=)
EP (1) EP2139886A4 (https=)
JP (1) JP2010521527A (https=)
CN (1) CN101679397A (https=)
AR (1) AR065845A1 (https=)
AU (1) AU2008232269A1 (https=)
CA (1) CA2681771A1 (https=)
CL (1) CL2008000838A1 (https=)
IL (1) IL201142A (https=)
MX (1) MX2009010193A (https=)
NZ (1) NZ580618A (https=)
TW (1) TWI417099B (https=)
WO (1) WO2008116308A1 (https=)
ZA (1) ZA200907458B (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987694A (zh) * 2011-12-16 2014-08-13 莱雅公司 具有7-氨基-1,2,3,4-四氢喹啉结构的成色剂、包含它们的染色组合物、方法及用途
CN108853509A (zh) * 2018-05-03 2018-11-23 浙江大学 抑郁症的治疗和药物组合物
CN109053712A (zh) * 2018-09-19 2018-12-21 南京大学连云港高新技术研究院 一种2-氨基噻吩-3-羧酸甲酯衍生物c15h22n2o5s的合成方法
CN109206385A (zh) * 2017-07-03 2019-01-15 扬子江药业集团有限公司 一种地佐辛杂质a及其同系物的制备方法
CN111650307A (zh) * 2020-07-13 2020-09-11 重庆医药高等专科学校 一种同时对酒中解热镇痛类药品非法添加物定性定量检测的方法及应用
WO2022056736A1 (zh) * 2020-09-16 2022-03-24 中国科学院深圳先进技术研究院 左氧氟沙星或其药物可接受盐在制备抗脑缺血再灌注损伤的药物或保健品中的应用
CN115073370A (zh) * 2021-03-10 2022-09-20 成都硕德药业有限公司 新型烷基氨类化合物或盐、异构体、其制备方法及用途

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100103799A (ko) * 2007-11-16 2010-09-28 네우렉슨 인코포레이티드 내장통을 치료하기 위한 인돌 화합물 및 방법
CA2705422A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
EP2343977A1 (en) * 2008-09-29 2011-07-20 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
FR2984318B1 (fr) 2011-12-16 2014-06-27 Oreal Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines cationiques, composition tinctoriale en comprenant, procedes et utilisations
EP2938341B1 (en) * 2012-12-31 2018-09-05 Sunovion Pharmaceuticals Inc. Heterocyclic compounds and methods of use thereof
US9486419B2 (en) 2013-04-17 2016-11-08 Ariel-University Research And Development Company CB2 receptor ligands for the treatment of psychiatric disorders
TW201506010A (zh) * 2013-06-26 2015-02-16 Daiichi Sankyo Co Ltd 三環雜環化合物之製造方法
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10092591B2 (en) 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
FR3072286B1 (fr) 2017-10-13 2022-08-12 Oreal 7-amino-1,2,3,4-tetrahydroquinoleines particuliers, procede et composition
KR20260049347A (ko) 2018-12-05 2026-04-13 노쓰웨스턴유니버시티 면역요법을 위한 뉴런 옥시드 신타제 억제제
WO2021127391A1 (en) 2019-12-20 2021-06-24 The Jackson Laboratory Molecular targets for addiction
US12213973B2 (en) 2021-10-18 2025-02-04 Northwestern University Bacterial nitric oxide synthase inhibitors
US20250221959A1 (en) * 2022-03-17 2025-07-10 Vasoceuticals, Inc. Combined use of individual compounds for treatment of chronic pain disorders
WO2025250859A1 (en) * 2024-05-31 2025-12-04 Septerna, Inc. 3,4-dihydroquinolin-2(1h)-one inhibitors of tshr

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087561A (en) 1975-12-22 1978-05-02 Canada Packers Limited Control of nitrosamine formation in nitride cured meat with 1,2,3,4-tetrahydro-quinoline compounds
FR2358151A1 (fr) 1976-03-31 1978-02-10 Roussel Uclaf Nouvelles benzazepines et leurs sels, procede de preparation et application a titre de medicaments
JPS5373571A (en) 1976-12-10 1978-06-30 Otsuka Pharmaceut Co Ltd Carbostyril derivatives
BE889929A (fr) 1980-08-12 1982-02-11 Glaxo Group Ltd Derives de l'indole, leur preparation et leurs utilisations therapeutiques
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
PT79699B (en) 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
ATE138658T1 (de) * 1987-12-30 1996-06-15 Orion Yhtymae Oy Heterocyclische verbindungen
US4963677A (en) * 1987-12-30 1990-10-16 Orion Corporation Ltd. Heterocyclic lactam compounds
US5847006A (en) * 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
EP0724570B1 (en) * 1993-10-21 1999-03-03 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
JPH09509156A (ja) * 1994-02-03 1997-09-16 ケンブリッジ・ニューロサイエンス・インコーポレーテッド 治療用グアニジン類
EP0759027B1 (en) * 1994-05-07 1999-08-04 Astra Aktiebolag Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
ES2236833T3 (es) * 1996-11-25 2005-07-16 THE PROCTER & GAMBLE COMPANY Compuestos heterociclicos de guanidinilo utiles como agonistas de receptores adrenergicos alfa 2.
IL130024A (en) 1996-11-25 2002-12-01 Procter & Gamble Compounds-2 Imidazoline and laminoindole Useful as agonists a - 2 - Adrenoceptors and pharmaceutical preparations containing them
JPH10265450A (ja) * 1997-03-25 1998-10-06 Mitsui Chem Inc 一酸化窒素合成酵素阻害作用を有する新規なアミジン誘導体
US6166030A (en) * 1997-05-05 2000-12-26 Astra Aktiebolag Compounds
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
EP1392317A4 (en) * 2001-05-16 2005-10-19 Antexpharma Inc SUBSTITUTED 1-BENZAZEPINE AND DERIVATIVES THEREOF
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
CA2370751A1 (en) * 2002-02-05 2003-08-05 Garth B.D. Shoemaker Fast and accurate rendering of pliable display technology distortions using pre-calculated texel coverages
MXPA04008822A (es) 2002-03-14 2004-11-26 Bayer Healthcare Ag Aroilpiridinonas monociclicas.
US20050171195A1 (en) * 2003-11-06 2005-08-04 Carroll William A. P2X7 antagonists for treating neuropathic pain
ES2357129T3 (es) 2005-04-13 2011-04-19 Neuraxon Inc. Compuestos indólicos sustituidos que tienen actividad inhibidora de nos.
WO2007017764A2 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity
BRPI0613430A2 (pt) 2005-07-13 2011-01-11 Hoffmann La Roche compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987694A (zh) * 2011-12-16 2014-08-13 莱雅公司 具有7-氨基-1,2,3,4-四氢喹啉结构的成色剂、包含它们的染色组合物、方法及用途
JP2015501826A (ja) * 2011-12-16 2015-01-19 ロレアル ７−アミノ−１，２，３，４−テトラヒドロキノリン構造を有するカプラー、それを含む染色組成物、方法及び使用
CN103987694B (zh) * 2011-12-16 2017-10-13 莱雅公司 具有7‑氨基‑1,2,3,4‑四氢喹啉结构的成色剂、包含它们的染色组合物、方法及用途
CN109206385A (zh) * 2017-07-03 2019-01-15 扬子江药业集团有限公司 一种地佐辛杂质a及其同系物的制备方法
CN109206385B (zh) * 2017-07-03 2022-04-22 扬子江药业集团有限公司 一种地佐辛杂质a及其同系物的制备方法
CN108853509A (zh) * 2018-05-03 2018-11-23 浙江大学 抑郁症的治疗和药物组合物
CN109053712A (zh) * 2018-09-19 2018-12-21 南京大学连云港高新技术研究院 一种2-氨基噻吩-3-羧酸甲酯衍生物c15h22n2o5s的合成方法
CN111650307A (zh) * 2020-07-13 2020-09-11 重庆医药高等专科学校 一种同时对酒中解热镇痛类药品非法添加物定性定量检测的方法及应用
WO2022056736A1 (zh) * 2020-09-16 2022-03-24 中国科学院深圳先进技术研究院 左氧氟沙星或其药物可接受盐在制备抗脑缺血再灌注损伤的药物或保健品中的应用
CN115073370A (zh) * 2021-03-10 2022-09-20 成都硕德药业有限公司 新型烷基氨类化合物或盐、异构体、其制备方法及用途
CN115073370B (zh) * 2021-03-10 2024-12-17 成都硕德药业有限公司 新型烷基氨类化合物或盐、异构体、其制备方法及用途

Also Published As

Publication number Publication date
AR065845A1 (es) 2009-07-08
ZA200907458B (en) 2011-01-26
US20080234237A1 (en) 2008-09-25
TW200902003A (en) 2009-01-16
NZ580618A (en) 2012-07-27
CA2681771A1 (en) 2008-10-02
WO2008116308A1 (en) 2008-10-02
JP2010521527A (ja) 2010-06-24
CL2008000838A1 (es) 2008-10-10
TWI417099B (zh) 2013-12-01
MX2009010193A (es) 2009-12-15
AU2008232269A1 (en) 2008-10-02
EP2139886A1 (en) 2010-01-06
US8173813B2 (en) 2012-05-08
IL201142A (en) 2013-12-31
EP2139886A4 (en) 2011-03-30
IL201142A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
TWI417099B (zh) 具抑制一氧化氮合成酶活性之喹諾酮、四氫喹啉及其相關化合物
TWI458726B (zh) 具有抑制一氧化氮合成酶活性的苯並噁嗪、苯並噻嗪及其相關化合物
JP5833804B2 (ja) Ｎｏｓ阻害活性を有する置換インドール化合物
US20090131503A1 (en) 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
JP5350219B2 (ja) Ｎｏｓ阻害活性を有する１，５および３，６−置換インドール化合物
KR20200020781A (ko) S1p1 활성을 조정하기 위한 화합물 및 그를 사용하는 방법
JP2008540638A (ja) ＮＯＳ阻害およびμオピオイドアゴニストの二重活性を有する置換ベンズイミダゾール化合物
HK1140754A (en) Quinolone and tetrahydroquinoline and related compounds having nos inhibitory activity
HK40016699B (zh) 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1140754

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100324

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1140754

Country of ref document: HK